Results 151 to 160 of about 61,313 (265)

Diabetes‐Induced Dysregulation of Purinergic Signaling in the Bladder Mucosa: Accelerated ATP Hydrolysis and Impaired Adenosine Uptake Promote Underactive Bladder Phenotype

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To explore molecular mechanisms underlying excessive extracellular adenosine (ADO) accumulation in the bladder lamina propria (LP) of mice with type 2 diabetes (T2D) induced by a high‐fat, high‐sucrose diet (HFHSD), conceivably leading to bladder underactivity.
Mahsa Borhani Peikani, Brian A. Perrino, Violeta N. Mutafova‐Yambolieva   +2 more
wiley   +1 more source

The effect of androgen supplementation on hair loss: A systematic review. [PDF]

JAAD Int
Gupta S, Bai JQA, Geng RSQ, Donovan J.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Androgen promotes oocyte development by upregulating gap junction intercellular communication activity in granulosa cells in mice. [PDF]

PeerJ
Zhang Y, Hu Y, Xu Y, Kuai Y, Wang S, Yu J.   +5 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

The risks of hormones to the inner ear. [PDF]

Braz J Otorhinolaryngol
Mangia LRL, Mezzalira R, Bittar RSM.
europepmc   +1 more source

Immune dysregulation in the prostates of C57BL/6Aire−/− mice mirrors that seen in human benign prostatic hyperplasia

The Journal of Pathology, EarlyView.
Abstract Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging men, resulting in significant morbidity. The etiologies of BPH are unknown, though chronic prostatic inflammation is known to promote hyperplasia, fibrotic remodeling, and therapeutic resistance in BPH.
Nadia A Lanman, Meaghan M Broman, Harish Kothandaraman, Gregory M Cresswell, Gada D Awdalkreem, Dilinaer Wusiman, Andree K Kolliegbo, Alexander P Glaser, Brian T Helfand, Renee E Vickman, Jiang Yang, Simon W Hayward, Timothy L Ratliff   +12 more
wiley   +1 more source

Testosterone Therapy in Women: A Literature Review of Clinical Indications, Dosing, Routes of Administration, and Safety. [PDF]

Cureus
Montero Bernaldez J, Burgess ER, Martinez R, Peñalver M.   +3 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

The persisting presence of absence in female sex development: a critical interdisciplinary reflection. [PDF]

Biol Sex Differ
Stammberger B, Steinbach X, Hornig N.
europepmc   +1 more source